

1. REVLIMID [package insert]. Summit, NJ: Celgene Corporation; 2017.
2. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. *J Hematol Oncol*. 2009;2:36.
3. National Institute of Health. Search Results: Multiple Myeloma Clinical Trial. Clinicaltrials.gov. Accessed February 21, 2017.
4. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014;371(10):906-917.
5. SEER Stat Fact Sheets: Myeloma. National Cancer Institute. SEER website. <http://seer.cancer.gov/statfacts/html/mulmy.html>. Accessed February 21, 2017.
6. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. *J Clin Oncol*. 2005;23(15):3412-3420.
7. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc*. 2003;78(1):21-33.
8. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. *Eur J Haematol*. 1994;53(4):207-212.
9. Data on file. Celgene Corporation.
10. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma in North America. *N Engl J Med*. 2007;357(21):2133-2142.
11. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. *N Engl J Med*. 2007;357(21):2123-2132.
12. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. *Br J Haematol*. 1998;102:1115-1123.
13. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed January 23, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

